Search research articles
Contact Us
Filters
Showing results (31-40 of 99) with videos related to
Page
of 10
Sort By:
Blood
|
June 26, 2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Nikoletta Lendvai, Patrick Hilden, Sean Devlin, et al.
Bone Marrow Transplantation
|
December 2, 2022
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
Anita D'Souza, Ruta Brazauskas, Bi Qing Teng, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 19, 2017
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial
Gary Deng, Sergio Giralt, David J Chung, et al.
Bone Marrow Transplantation
|
May 6, 2023
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
Meera Mohan, Siegfried Janz, Ruta Brazauskas, et al.
European Heart Journal Open
|
September 22, 2025
Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis
Kristine H Jang, Anthony F Yu, Heather Landau, et al.
Leukemia & Lymphoma
|
December 3, 2016
Proteomic profiling in plasma cell disorders: a feasibility study
Sham Mailankody, Sean M Devlin, Neha Korde, et al.
Leukemia & Lymphoma
|
August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
Heather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
Leukemia & Lymphoma
|
October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency
Adebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Adam R Bryant, Patrick Hilden, Sergio Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2015
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma
Eric Smith, Sean M Devlin, Satyajit Kosuri, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 99) with videos related to
Sort By:
Page
of 10
Blood
|
June 26, 2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Nikoletta Lendvai, Patrick Hilden, Sean Devlin, et al.
Bone Marrow Transplantation
|
December 2, 2022
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
Anita D'Souza, Ruta Brazauskas, Bi Qing Teng, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 19, 2017
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial
Gary Deng, Sergio Giralt, David J Chung, et al.
Bone Marrow Transplantation
|
May 6, 2023
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
Meera Mohan, Siegfried Janz, Ruta Brazauskas, et al.
European Heart Journal Open
|
September 22, 2025
Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis
Kristine H Jang, Anthony F Yu, Heather Landau, et al.
Leukemia & Lymphoma
|
December 3, 2016
Proteomic profiling in plasma cell disorders: a feasibility study
Sham Mailankody, Sean M Devlin, Neha Korde, et al.
Leukemia & Lymphoma
|
August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
Heather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
Leukemia & Lymphoma
|
October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency
Adebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Adam R Bryant, Patrick Hilden, Sergio Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2015
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma
Eric Smith, Sean M Devlin, Satyajit Kosuri, et al.
Page
of 10